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Abstract
Recent studies have demonstrated nuclear export by papillomavirus E1 proteins, but the requisite export sequence(s) for bovine papillomavirus
(BPV)E1were not defined. In this report we identify three functional nuclear export sequences (NES) present in BPVE1, withNES2 being the strongest
in reporter assays. Nuclear localization of BPV1 E1 was modulated by over- or under-expression of CRM1, the major cellular exportin, and export was
strongly reduced by the CRM1 inhibitor, LeptomycinB, indicating that E1 export occurs primarily through a CRM1-dependent process. Consistent with
the in vivo functional results, E1 bound CRM1 in an in vitro pull-down assay. In addition, sumoylated E1 bound CRM1 more effectively than
unmodified E1, suggesting that E1 export may be regulated by SUMOmodification. Lastly, an E1NES2mutant accumulated in the nucleus to a greater
extent than wild-type E1, yet was defective for viral origin replication in vivo. However, NES2 exhibited no intrinsic replication defect in an in vitro
replication assay, implying that nucleocytoplasmic shuttling may be required to maintain E1 in a replication competent state.
© 2008 Elsevier Inc. All rights reserved.Keywords: Nuclear export sequence; NES; CRM1; E1; Sumoylation; NLSIntroduction
The papillomavirus (PV) E1 protein (PV-E1), one of the esti-
mated eight different proteins produced by papillomaviruses
during infection, constitutes the most promising target for the
development of anti-papillomavirus therapies owing to its well
characterized DNA helicase activity, essential for the maintenance
and replication of the viral DNA. Comparative analyses among
the PV-E1 proteins of numerous viral strains revealed the presence
of threemain domainswithin PV-E1, namely anN-terminal region
of poorly defined activity, a spacer domain, and a C-terminal
domain showing the typical features associated to DNA helicases,
including DNA binding, ATP binding, and oligomerization
(Wilson et al., 2002). Numerous reports have characterized the
three-dimensional structure of the DNA binding domain for two
PV-E1 proteins, those produced by the human papillomavirus 18
(HPV18-E1) and the bovine papillomavirus E1 (BPV-E1) (Auster⁎ Corresponding author. Fax: +1 979 845 3479.
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doi:10.1016/j.virol.2007.12.017and Joshua-Tor, 2004; Enemark et al., 2000; Enemark and Joshua-
Tor, 2006; Enemark et al., 2002). Such studies have produced
significant insights into the molecular characteristics mediating
the enzymatic activity of these proteins. However, several aspects
of the molecular mechanisms regulating the function of this viral
protein remain enigmatic. Perhaps the most intriguing among
these are the mechanisms governing the cellular localization of
PV-E1. PV-E1 exerts its helicase role in the cell nucleus and
therefore it must contain specific amino acid sequences that direct
it to this cellular compartment. The presence of such sequences,
known as Nuclear Localization Signals (NLSs), has been well
characterized in both HPV-E1 and BPV-E1 (Leng and Wilson,
1994; Lentz et al., 1993; Yu et al., 2007), and a recent study has
determined that the nuclear traffic of BPV-E1 is mediated by the
classic nuclear import pathway involving the assembly of an
importin α/β complex with the NLS of BPV-E1 (Bian et al.,
2007). Thus, significant knowledge of the molecular mechanisms
mediating the nuclear import of PV-E1 proteins is currently
available.
Intriguingly, however, a recent report has indicated the
presence in HPV11-E1 of a signal, known as Nuclear Export
Signal (NES), that directs the protein out of the nucleus (Deng
Fig. 1. BPV E1 is actively exported out of the nucleus. HeLa cells were transfected
with an expression plasmid coding for an EGFP fusion of BPV E1 (EGFP–E1).
24 h post-transfection, the cells were partially permeabilized with digitonin,
washed several times, and incubated in 1× Transport Buffer alone (TB, lanes 1
and 2) or 1× Transport Buffer supplemented with 20% rabbit reticulocyte extract
(TB+ReticExt, lanes 3 and 4), for 1 h at 37 °C. The resulting supernatant (S) was
collected and immunoprecipitated with anti-GFP antibodies (lanes 2 and 4),
whereas the residual nuclei (N) of the permeabilized cells were solubilized and
lysed in 2× Sample Buffer (lanes 1 and 3). Both, the immunoprecipitated samples
and the solubilized nuclei were analyzed by SDS-PAGE and immunoblotting using
anti-GFP antibodies. Arrow: EGFP–E1. Star: High molecular weight form(s) of
EGFP–E1 (likely to correspond to sumoylated forms).
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nuclear export of E1 mediated by the cellular nuclear export
factor CRM1, thus preventing the nuclear accumulation of E1.
Importantly, phosphorylation of residues located near the NES
neutralized its activity and allowed nuclear accumulation of E1.
The kinase responsible for this phosphorylation event was
identified as a cyclin-dependent kinase (CDK), linking the
cellular localization of the HPV11-E1 protein with the cell cycle
of its host cell. Similarly, the presence of a NES in BPV-E1 has
also been postulated in a recent study, although the specific
location of this signal in BPV-E1 was not identified (Hsu et al.,
2007). According to this study, and in sharp contrast with the
NES identified in HPV11-E1, the putative BPV-E1 NES appears
constitutively inactive, requiring the phosphorylation of Ser 283,
also by a CDK, to become active. The presence of a NES in both
HPV11-E1 and BPV-E1 suggests that nuclear shuttling may
constitute an evolutionary conserved mechanism that plays an
important role in maintaining and/or regulating the activity of
PV-E1.
In this study, we have verified that the BPV-E1 protein is
exported from the nucleus by an active mechanism that involves
the nuclear export factor CRM1. Furthermore, we have mapped
three nuclear export signals within BPV-E1, the strongest of
which is fully dependent on CRM1 and is constitutively active
both in reporter chimeric constructs and in the full-length BPV-
E1 protein. The other two NES elements exert limited activity
under the conditions tested, but appear to function by means of
cellular nuclear export factors other than CRM1, therefore
providing BPV-E1 with the ability to utilize alternative nuclear
export pathways. Our data also indicates that nuclear shuttling
may play an important role in keeping BPV-E1 in an active stage,
as mutations affecting exclusively the activity of the strongest
NES render the protein virtually unable to trigger the replication
of a plasmid containing a viral origin of replication. Finally, we
also present data indicating that sumoylation may play a
regulatory role in nuclear shuttling by increasing BPV-E1's
affinity toward CRM1, and redirect previous conclusions on the
role of sumoylation for the nuclear localization of BPV-E1.
Results
The bovine papillomavirus E1 protein is actively exported from
the cell nucleus
Like most DNA helicases, the papillomavirus E1 protein is
targeted to the nucleus owing to the presence of a nuclear
localization signal (NLS) on its primary structure (Leng and
Wilson, 1994; Lentz et al., 1993; Yu et al., 2007). Interestingly, a
recent study by Deng et al. reported the presence of a nuclear
export signal (NES) in the human papillomavirus 11 (HPV11)
E1 protein and postulated that phosphorylation of a nearby
serine residue by cell-cycle dependent kinases regulated the
accessibility of the NES, therefore linking the cellular localiza-
tion of the HPV11 E1 viral helicase with the progression through
the cell cycle of the host cell (Deng et al., 2004). Although in that
study the authors indicated the absence of an NES in the equi-
valent region of the bovine papillomavirus E1 protein (BPV E1),we hypothesized that the function of BPV E1 could also be
regulated by nuclear export potentially mediated by still uniden-
tified NESs located elsewhere in the protein.
To verify if BPV E1 is actively exported from the cell nucleus,
HeLa cells transfected with the pEGFP–E1 plasmid (which codes
for a EGFP fusion of BPV E1, EGFP–E1) were partially permea-
bilized with digitonin, washed several times to eliminate both any
residual cytosolic EGFP–E1 and the cellular soluble factors
required for nucleocytoplasmic traffic, and incubated in transport
buffer with or without reticulocyte extract. After incubation, the
resulting supernatants were collected, immunoprecipitated with
rabbit serum against GFP, and analyzed by immunoblotting using
monoclonal antibodies to GFP. Incubation of the permeabilized
HeLa cells with transport buffer alone did not allow the export of
EGFP–E1 out of the nucleus as no EGFP–E1 was detected in the
resulting supernatant (Fig. 1, lanes 1 and 2). In contrast, incu-
bation of the permeabilized cells in transport buffer supplemented
with reticulocyte extract resulted in the export of EGFP–E1 out of
the nucleus, as EGFP–E1 was readily detected in the resulting
supernatant and a significant decrease in the fraction of EGFP–E1
remaining in the nucleus was also observed (Fig. 1, lanes 3 and 4).
Interestingly, under these conditions a high molecular weight
form of EGFP–E1 was also detected in the supernatant (Fig. 1,
asterisk); the identity of this form has not been established, but
could represent sumoylated E1 (see below). Since reticulocyte
extracts are rich in Ran, importins, and exportins, therefore pro-
viding an optimal source of nucleocytoplasmic traffic factors, the
above data indicate that EGFP–E1 is actively transported from the
nucleus as its export is dependent on cellular factors. Therefore,
BPV E1, like HPV11 E1, must contain signals that allow its
nuclear export.
The nuclear export of BPV E1 is mainly regulated by CRM1
To identify putative sequences that could mediate the nuclear
export of BPV E1, we scanned the primary structure of BPV
E1 for the presence of consensus motifs known to serve as
NESs for other proteins. We identified two leucine-rich NESs of
the L(X2–3)L(X2–3)LXL type (where L represents leucine or
any other large hydrophobic residue, namely valine, isoleucine,
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(NES1), and residues 409–418 (NES2) of BPV E1. Addition-
ally, we also found a sequence exhibiting the L(X8)L(X3)L
motif (where L specifically indicates leucine), a type of NES
recently identified in the Cdk inhibitor p27 (Connor et al., 2003),
spanning residues 140–153 (NES3) of BPV E1. Finally, we also
identified another sequence related to the same L(X8)L(X3)L
motif but containing methionine instead of leucine in the first
position, spanning residues 262–275 (NES4) (Fig. 2A). All
of the putative NES motifs indicated above are expected to
mediate nuclear export by providing an interacting signal with
the nuclear export receptor CRM1/Exportin 1. Therefore, we
tested the ability of CRM1 to interact with BPV E1 using in vitro
translated 35S-labeled BPV E1 and bacterially expressed
purified GST-CRM1. The 35S-BPV E1 did not exhibit any
significant binding to glutathione–sepharose beads when incu-
bated in the presence of GST. However, when GST-CRM1 was
used as bait, significant amounts of 35S-BPV E1 were co-
purified with the beads (Fig. 2B). Furthermore, phosphordensi-
tometry analysis indicated that the amount of 35S-BPV E1
recovered on the beads increased proportionally to the amount of
GST-CRM1 loaded in the beads, therefore indicating a specific
interaction between BPV E1 and CRM1 (Fig. 2C).
Since the in vitro binding assay suggested that CRM1 could
act as an exportin for the nuclear export of BPV E1, we sought toFig. 2. BPVE1 contains four putative CRM1-dependent Nuclear Export Signals (NES
serve as NESs for other proteins. The numbers to the left indicate the position of the f
Similar motifs found in other proteins and the known consensus motifs are presented f
parenthesis. (B) Pull-down assays performed with purified GSTor GST-CRM1 and tra
as indicated on top of each lane. The samples were analyzed by SDS-PAGE and quant
input BPV E1 that remained bound to the beads after the pull-down procedure presedetermine if CRM1 affected the cellular localization of BPV E1.
To this end we employed Leptomycin B (LMB), a fungal cyto-
toxin that acts as an inhibitor of CRM1-mediated nuclear export
by disrupting the interaction of CRM1 with its cargo through the
modification of a cysteine residue located in the cargo binding
pocket in CRM1 (Kudo et al., 1999; Wolff et al., 1997). CHO-K1
cells transfected with pEGFP–E1 were incubated for 6 h in the
presence of cyclohexamide with or without LMB, and the cellular
localization of EGFP–E1 was determined by fluorescence
microscopy. As a control for these experiments we used the
plasmid pREV1.4(NES3)GFP (Henderson and Eleftheriou,
2000), which codes for a fusion of the HIV-REV protein with
GFP (REV–GFP). In this plasmid, the NES in REV was
inactivated by alanine substitutions of the central leucines, and an
active copy (free of mutations) of the NES was inserted in the
junction between REV and GFP. The REV–GFP fusion protein
produced upon transfection of the plasmid in mammalian cell
lines shuttles continuously between the nucleus and the cytosol,
owing to the strong NLS and NES present on the REV sequence,
and exhibits a characteristic cytoplasmic and nucleolar localiza-
tion (Fig. 3A, untreated), this last due to the ability of REV to
interact with nucleolar components. Furthermore, the nuclear
import of REV–GFP can be significantly decreased by treatment
with actinomycin D (ActD)(Fig. 3A,+ActD), and its nuclear
export is fully abolished by LMB (Fig. 3A,+ActD+LMB). Ins) and binds to CRM1. (A) The presence in BPVE1 of consensusmotifs known to
irst amino acid residue depicted in the primary sequence of the indicated protein.
or comparison. The name given to each NES identified in BPV E1 is indicated in
nslated BPVE1. The pull-downs were performed using different amounts of bait,
ified by phosphordensitometry. (C) Quantitative data indicating the percentage of
nted in B.
Fig. 3. LMB significantly decreases the nuclear export of BPV E1. CHO-K1 cells were transfected with pEGFP–E1 or with the control plasmid pREV1.4(NES3)GFP,
and 16 h post-transfection the cells were incubated for 6 h in the presence of cyclohexamide with or without Leptomycin B (LMB) and actinomycin D (Act D), and the
cellular localization of the EGFP fusion proteins produced was determined by fluorescence microscopy or biochemical fractionation. (A) Cellular localization of the
mutant REV–GFP protein encoded by plasmid pREV1.4(NES3)GFP with GFP (REV–GFP) upon treatment with Act D and LMB. (B) Effect of LMB treatment on the
cellular localization of E1-GFP, as compared with the effect of LMB treatment on the cellular localization of REV–GFP. (C) Biochemical fractionation of LMB-treated
CHO cells into nuclear (N) and cytoplasmic (C) fractions. Both fractions were resolved by SDS-PAGE and immunoblotted with anti-GFP. The arrow indicates full-
length EGFP–E1, and the star indicates a low molecular weight species present in both the nuclear and cytoplasmic fractions. This low molecular weight species is
slightly larger than EGFP and is likely EGFP with a small portion of E1.
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(NES3)GFP or pEGFP–E1 we observed that LMB treatment
produced a complete re-localization of REV–GFP to the nucleus,
more specifically to the nucleolus, and LMB treatment produced a
substantial but incomplete redistribution of EGFP–E1 to the
nucleus (Fig. 3B). Biochemical fractionation experiments
(Fig. 3C.) revealed that there was a low molecular weight form
derived from the EGFP–E1 that was present in the cytoplasmic
fraction and likely accounted for the residual cytoplasmic fluo-
rescence. These results suggest that E1 export is mediated
primarily through a CRM1-dependent pathway.
If CRM1 is the primary exporter of E1, then fluctuations in
the cellular amount of CRM1 should exert substantial effects on
the nuclear export of BPV E1. This could be tested by co-
transfecting mammalian cells with pEGFP–E1 and pcDNA3-
CRM1, a previously reported plasmid construct that over-ex-
pressions CRM1 and leads to a concomitant cytoplasmic redis-
tribution of nuclear proteins containing CRM1-dependent NESs
(Boyle et al., 1999). Alternatively, transfecting a plasmid coding
for a hairpin-forming sequence complementary to sequences inCRM1 should induce an RNAi response against CRM1 leading
to decreased CRM1 levels and a subsequent increase in nuclear
accumulation of proteins containing CRM1-dependent NESs.
To develop a plasmid capable of inducing RNAi against CRM1
upon transfection, we selected two sequences derived from the
human CRM1 gene transcript (accession number NM_003400),
and developed oligonucleotides containing inverted repeats of
the selected sequences. The inverted repeats were designed to
produce hairpins with a 19-nucleotide stem and a 9-nucleotide
loop (Supplementary Fig. 1A). The oligonucleotides were
cloned into the pSilencer™ 4.1-CMV puro vector (Ambion),
producing the plasmids pSIL-CRM1A (containing a sequence
derived from the junction between exons 2 and 3 in CRM1) and
pSIL-CRM1B (containing a sequence derived from the 3′ end of
exon 3 in CRM1) (Supplementary Fig. 1A). As a control, we also
generated a plasmid containing a scrambled sequence forming a
19-nucleotide stem lacking significant similarity to any known
transcript, denominated pSIL-Scrambled. To evaluate the effec-
tiveness of these constructs in inducing RNAi against CRM1
and therefore down-regulating the cellular levels of CRM1,
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and the pREV1.4(NES3)GFP plasmid, and the cellular localiza-
tion of REV–GFP was evaluated in the transfected cells
approximately 60 h post-transfection. This relatively long
incubation time after transfection was essential to induce a
significant decrease in the cellular amount of CRM1 due to the
previously reported high stability of this protein (Fornerod et al.,
1997). The large majority of the CHO-K1 cells transfected with
pREV1.4(NES3)GFP alone or in conjunction with the pSIL-
CRM1B or the pSIL-Scrambled plasmids exhibited a predomi-
nantly cytosolic distribution of REV–GFP upon ActD treatment
(Supplementary Fig. 1B,+ActD,+ActD+pSIL-CRM1B,+ActD
+pSIL-Scrambled, and 1C). In contrast, the large majority of the
cells co-transfected with pSIL-CRM1A exhibited a mostly
nucleolar distribution of REV–GFP, even upon treatment with
ActD (Supplementary Fig. 1B,+ActD+pSIL-CRM1A, and 1C),
therefore indicating that the pSIL-CRM1A effectively induced
an RNAi response directed against CRM1 which resulted in
diminished nuclear export of CRM1-dependent cargo.
Next, we tested the ability of CRM1 to induce changes in the
cellular distribution of EGFP–E1 upon conditions of over and
under-expression. Initial co-transfection experiments in CHO-K1
were largely unsuccessful due to the toxic effects induced by the
over-expression of BPV E1. This intrinsic feature of BPV E1 was
implied by the observation that by 60 h post-transfection the only
cells displaying significant expression of BPV E1 also exhibited
a largely disrupted morphology characterized by a round shape,
lack of cytoplasmic extensions, and an apparent lack of cyto-
plasm as the nucleus seemed to occupy the full volume of the
cell. To overcome this difficulty, we opted for a sequential trans-Fig. 4. The cellular distribution of BPV E1 is dictated by the abundance of CRM1
produce either an increase or a substantial decrease in the cellular levels of CRM1, r
based plasmid containing a scrambled sequence known not to target any specific c
pEGFP–E1 or pREV1.4(NES3)GFP plasmids, treated with cyclohexamide (CHX) an
transfection. The plasmid used in the first transfection is indicated on top of each pane
cells shown are representative of the cellular localization observed for the indicatedfection strategy. Briefly, HeLa cells were transfected with either
pcDNA3-CRM1, pSIL-CRM1A, or pSIL-Scrambled, and main-
tained in culture for 36 h, the cells transfected with the pSilencer-
based plasmids being maintained in the presence of puromycin to
select for transfected cells. Then, the cells were re-transfectedwith
the pEGFP–E1 or pREV1.4(NES3)GFP plasmids, treated with
cyclohexamide (CHX) and/or ActD, fixed, and analyzed by
fluorescence microscopy 24 h after the second transfection. In
these experiments we consistently observed that over-expression
of CRM1 led to a homogeneous distribution of BPV E1 through-
out the cell (Fig. 4, +pcDNA3-CRM1), making the nucleus un-
apparent. In sharp contrast, under-expression of CRM1
consistently led to a substantial decrease in the cytosolic signal
observed, and a significant increase in the nuclear signal produced
(Fig. 4, +pSIL-CRM1A+ActD). Both profiles were substantially
different from the normal distribution of EGFP–E1 observed
in cells co-transfected with the scrambled siRNA, in which
EGFP–E1 appeared predominantly nuclear but exhibited also
significant cytosolic distribution (Fig. 4,+pSIL-SCRAM+ActD).
The efficacy of this approach to induce over- and under-
expression of CRM1 was indicated by the cellular distribution
of REV–GFP in the cells co-transfected with pREV1.4(NES3)
GFP. As expected, REV–GFP appeared almost exclusively cyto-
plasmic in cells over-expressing CRM1 even in the absence of
ActD (Fig. 4,+pcDNA3-CRM1), was mostly cytosolic upon
ActD treatment in cells transfected with the scrambled siRNA
(Fig. 4,+pSIL-SCRAM+ActD), and displayed a predominantly
nucleolar distribution in cells co-transfected with pSIL-CRM1A
even upon ActD treatment (Fig. 4,+pSIL-CRM1A+ActD).
Altogether, these observations demonstrated that the cellular. HeLa cells were transfected with either pcDNA3-CRM1 or pSIL-CRM1A to
espectively. A third group of cells was transfected with pSIL-SCRAM, a pSIL-
ellular gene. Thirty-six hours post-transfection the cells were transfected with
d/or ActD, fixed, and analyzed by fluorescence microscopy 24 h after the second
l, whereas the plasmid used in the second transfection is indicated on the left. The
proteins under the conditions described.
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dance of CRM1, therefore supporting the conclusion that CRM1
is the main nuclear export factor for BPV E1.
BPV E1 contains three functional leucine-rich nuclear export
signals
Next, we evaluated the functional activity of the individual
putative NESs identified in BPV E1. For these experiments, theFig. 5.NES2, the strongest NES inBPVE1, is sensitive to theCRM1-inhibitory activity o
where the putative nuclear export signals (NESs) identified inBPVE1were introduced to
original cloning sites used to introduce the REVNES in the parental pREV1.4(NES3)GF
introduction of the linker sequence depicted between the mutated BamHI and AgeI. Th
associated to the length of the NES expressed, and contains newBamHI andAgeI sites. T
proteins by directional cloning of the different NESs between the BamHI and AgeI sites
NES–GFP fusion proteins, and the cellular localization of the encoded proteinswas deter
different NESs identified in BPVE1. The cells shown are representative of the localizati
method described by Henderson and Eleftheriou (Henderson and Eleftheriou, 2000), w
sequence that lacks any NES activity, and 9+ being the strongest NES possible. LMB
reporter carrying the indicated putative NES.NES element located between the BamHI and AgeI sites on the
parental pREV1.4(NES3)GFP plasmid was replaced with
each of the putative NESs identified in BPV E1. To prevent
constraints associated with the length of the NES expressed
between the BamHI and AgeI sites, an adaptor sequence was
introduced between the BamHI/AgeI sites on pREV1.4(NES3)
GFP. The adaptor was designed to introduce mutations in the
original BamHI and AgeI sites, therefore inactivating them
(Fig. 5A, unmarked horizontal lines above the sequence), whilef LMB. (A)Nucleotide and amino acid sequences of the region in pREV/GFP/Adpt
test their activity. The unlabeled lines on top of the nucleotide sequence indicate the
P construct. Those cloning sites were mutated and the REVNES eliminated by the
is linker extends the sequence between REVand GFP, thus preventing constraints
hus, the pREV/GFP/Adpt vector allows the expression of REV–NES–GFP fusion
. (B) HeLa cells were transfected with the different constructs coding for the REV–
mined by fluorescencemicroscopy. The figure summarizes the data obtained for the
on of each REV–NES–GFP. NES activity wasmeasured and rated according to the
hich gives an activity value between 0 and 9+ to a putative NES, with 0 being a
Sensitivity indicates whether LMB treatment prevented the nuclear export of the
Table 1
Intracellular distribution of NES constructs
Construct CHX alone CHX+ActD CHX+ActD+
LMB
NES
activity⁎
Nuc N/C Cyt Nuc N/C Cyt Nuc N/C Cyt
pREV4.1
(NES3)
EGFP
31 61 8 3 32.5 64.5 97.5 2.5 0 5+
pREV/EGFP/
Adpt-1
99 1 0 97.9 2.1 0 97.5 2.5 0 0
MVM-NS2 80 20 0 70.5 29.5 0 88.5 11.5 0 1+
NES1 98 2 0 95 5 0 97.5 2.5 0 0
NES1M 96.5 3.5 0 91.5 8.5 0 93 6.5 0.5 0
NES2 74 26 0 41 59 0 96 4 0 2+
NES2M 96.5 3.5 0 94.5 5.5 0 95 5 0 0
NES3 78.5 21.5 0 67 33 0 76 24 0 1+
NES3M 97.5 2.5 0 92.5 7.5 0 89.5 10.5 0 0
NES4 85.5 14.5 0 69 30.5 0.5 76 24 0 1+
NES4M ND ND ND ND ND ND ND ND ND 0
⁎The NES activity is given according to the measuring method developed by
Henderson and Eleftheriou (Henderson and Eleftheriou, 2000).
Nuc: Nuclear; N/C: Nuclear and cytosolic; Cyt: Cytosolic; ND: Not determined;
CHX: cycloheximide; ActD: actinomycin D; LMB: leptomycin B.
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section of the adaptor (Fig. 5A, marked horizontal lines above
the sequence). Next, complementary oligonucleotides coding
for the putative E1 NES elements were cloned into the modified
pREV1.4(NES3)GFP (designated pREV/GFP/Adpt). The
resulting constructs were transfected into HeLa cells and the
nuclear export activity of each putative NES was evaluated by
counting the number of cells exhibiting only nuclear, both
nuclear and cytoplasmic, and only cytoplasmic distribution ofFig. 6. The conserved hydrophobic residues in the BPV E1 NESs are responsible for
nuclear export signals NES2 and NES3 were substituted by alanine residues in their
cellular localization of the GFP reporter was assessed by transfection of the mutated co
presented as a negative control. The sequences shown correspond to the actual seque
sites on the pREV/GFP/Adpt vector (between proline and glycine, see Fig. 5). WT: W
are indicated by bars.the GFP reporter in the absence and presence of ActD and LMB,
according to the method previously reported by Henderson and
Eleftheriou (Henderson and Eleftheriou, 2000). While the
reporter encoded by pREV/GFP/Adpt exhibited exclusively
nuclear localization, three out of the four putative NESs
identified in BPV E1, namely NES2, NES3, and NES4, had
the ability to induce some cytosolic localization of the reporter
protein (Fig. 5B). Although for all these NESs the cytosolic
localization of the reporter increased upon ActD treatment
(Table 1), the percentage of cells exhibiting some cytosolic
fluorescence remained low even upon ActD treatment, with
NES2 being the one that induced the highest percentage of cells
displaying some cytosolic fluorescence. This indicated that the
strengths of the BPV E1 NESs were weak compared to the REV-
NES and other previously reported NESs (Henderson and
Eleftheriou, 2000). Quantitative comparison by the scoring
system developed by Henderson and Eleftheriou confirmed the
qualitative observations (Table 1 and Fig. 5B). Interestingly,
LMB treatment completely inhibited the activity of NES2 but
had no little or no effect on the activity of both NES3 and NES4
(Table 1 and Fig. 5B).
To confirm that the conserved hydrophobic residues in the
BPV E1 NESs were responsible for their function, we
introduced double alanine substitutions for two of the bulky
hydrophobic residues in both E1 NES2 and NES3, and the
resulting mutants were transfected into both Cos1 cells (Fig. 6)
and HeLa cells (data not shown). In both cell lines, alanine
replacements of two of the residues postulated to constitute part
of the NESs identified in NES2 and NES3 fully eliminated their
activity, therefore confirming their functional role as constitu-
ents of the NESs identified.their function. Two hydrophobic residues considered functional components of
respective pREV/GFP/Adpt constructs. The effect of these replacements on the
nstructs into COS1 cells followed by fluorescence microscopy analysis. NES1 is
nce coded by the nucleotide sequence placed between the BamHI and the AgeI
ild-type sequence. MU: Mutated sequence. The residues substituted with alanine
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The observation that LMB inhibited the nuclear export
activity mediated by NES2 but not the export mediated by
NES3 or NES4 suggested that perhaps NES2 was the only NES
in BPV-E1 that used CRM1 as exportin. To test if the functional
NESs identified worked in a CRM1-dependent manner, we
transfected the pREV/GFP/Adpt constructs containing the
different NESs into HeLa cells either on their own or together
with the pcDNA3-CRM1 plasmid, treated the cells with either
CHX+ActD or CHX+ActD+LMB, and determined the percen-
tage of cells exhibiting nuclear, nuclear and cytosolic, and
cytosolic fluorescence. As expected, both of the previously
characterized CRM1-dependent NESs tested, MVM-NS2 and
the HIV-REV NES contained in pREV4.1(NES3)GFP, exhib-
ited a significant increase in cytoplasmic fluorescence upon
CRM1 over-expression (Fig. 7). However, out of the three
functional NESs identified in BPV E1, only NES2 exhibited a
substantial increase in cytosolic localization upon CRM1 over-
expression (Fig. 7A), with over 50% of the cells exhibiting
exclusively cytoplasmic fluorescence when the cells were
treated with CHX+ActD (Fig. 7B). For NES3 and NES4, there
were no cells exhibiting an exclusively cytoplasmic E1 signal
after CRM1 over-expression, and in fact the percentage of cells
exhibiting any cytosolic signal decreased slightly. Furthermore,
for the NES2 construct, LMB treatment led to a fully nuclear
distribution of the reporter, whereas for NES3 and NES4 LMB
treatment did not exert significant effects (data not shown).Fig. 7. NES2, the strongest NES in BPV E1, is CRM1-dependent. HeLa cells were tr
combination with the pcDNA3-CRM1 plasmid. The transfected cells were treated wi
expressingCRM1on the cellular localization of the different REV–NES–GFP fusion p
and cytosolic, and cytosolic fluorescence. (A) Representative images of cells expressin
CRM1. (B) Quantitative data indicating the cellular distribution of the different R
presented as percentage of cells exhibiting either exclusively nuclear, nuclear and cyAltogether, these data indicate that the nuclear export activity of
NES2 is CRM1-dependent, whereas the nuclear export activity
of NES3 and NES4 is insensitive to CRM1 levels and appears to
be mediated by other exportin(s).
Inactivation of NES2 in the context of E1 protein increases the
nuclear distribution of E1 and negatively affects replication
activity
The above results implicated NES2 as a significant CRM1-
dependent export motif, and we next sought to confirm this
within the context of E1 itself. The use of EGFP fusions allowed
us to determine the cellular localization of both wild-type and
the NES 2 mutant form of BPV E1 (referred to as NES2M). The
double alanine replacement mutant of NES2 (I413 and L416),
which inactivates NES2 in the pREV/GFP/Adpt construct, also
produced a dramatic change in the cellular distribution of the
EGFP–E1 fusion. While the WT BPV E1 exhibited significant
nuclear and cytoplasmic distribution, the NES2M mutant
exhibited a substantial increase in nuclear localization accom-
panied by a marked decrease in cytoplasmic localization
(Fig. 8A). Therefore, inactivation of NES2 markedly decreases
the export of BPV E1 thus resulting in increased BPV E1
nuclear localization, in agreement with our previous observa-
tion that NES2 is the strongest NES in BPV E1.
Functionally, BPV E1 carries out its helicase activity in the
nucleus of the cell, and several previous reports have indicated
that regulation of the nuclear localization of BPV E1 is a criticalansfected with the different pREV/GFP/Adpt–NES constructs either alone or in
th CHX and ActD and analyzed by fluorescence microscopy. The effect of over-
roteinswas quantified by counting the number of cells exhibiting nuclear, nuclear
g REVNES, BPVE1NES2, and BPVE1NES3with andwithout over-expressed
EV–NES–GFP constructs with or without over-expressed CRM1. The data is
toplasmic, or exclusively cytoplasmic fluorescence.
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determine if the altered nuclear export of the NES2 mutant E1
would exert any effect on BPV E1 replication activity. We
performed transient BPV DNA replication assays by co-trans-
fecting CHO-K1 cells with an expression plasmid for BPV E2
(pCGE2), a plasmid carrying the BPV origin of replication
(pBOR), and an expression plasmid for EGFP fusions of either
the wild-type or the NES2 mutant form of BPV E1. Replicated
pBOR was quantified using a modification of a previously
reported PCR based method (Titolo et al., 1999). To ensure that
any replication differences observed among samples were not
due to transfection differences, we also measured the amount of
E1 expression plasmid in each group of transfected cells in the
same set of PCR reactions. Interestingly, even though there was
increased nuclear localization by the NES2M mutant, there was
decreased replication of the pBOR plasmid (Fig. 8B). As similar
transfection efficiencies were achieved among all samples
tested, as demonstrated by the E1 control, the diminished repli-
cation activity observed in cells transfected with the NES2M
mutant suggests that either nuclear shuttling is important to
maintain the activity of BPV E1, or the substitutions introduced
in the NES2Mmutant negatively affect the enzymatic activity ofFig. 8. Inactivation of NES2 affects the replication activity of BPV E1. CHO-K1 cells w
(WT), a NES2 mutant (NES2M), or a K514R mutant of BPV E1, either alone or in com
plasmid), and pCGE2 (coding for the BPVE2 protein). The transfected cells were either
of methylated DNA, and PCR amplification in the presence of 32P-dCTP to detect repl
replication assays. The location of the PCR products derived from pBOR and E1 are ind
(in μL) of in vitro translated wild-type E1 (WT), NES2 mutant E1, or a Mock sample as
primed with DNAwhich did not encode E1. Values shown are the average of either 2 o
reactions (M is the mock reaction, W is the wild-type E1, and MT is the NES2 mutantBPV E1. Importantly, although the activity of the NES2M mu-
tant in the transient replication assays was approximately 1/10th
of the activity of the WT protein, it was consistently more active
than the K514R mutant, a previously described BPV E1 mutant
(see below).
To evaluate intrinsic replication activity of the NES2 mutant,
in vitro replication assays were performed (Fig. 8C). For these
studies, both the WTand mutant E1 proteins were synthesized in
vitro to avoid any issues with differences in modifications
or purification properties that might result from their somewhat
different intracellular distributions. In contrast to the in vivo
results, NES2Mwas as active asWTE1, indicating that these two
amino acid changes did not disrupt E1 activities necessary for
DNA replication. Consequently, the in vivo replication deficit
appears to be related to reduce nuclear-cytoplasmic shuttling.
Sumoylation enhances the interaction of BPV E1 with CRM1
BPV E1 is post-translationally modified by the covalent
attachment of SUMO (Rangasamy and Wilson, 2000), a small
ubiquitin-related modifier, and this modification is enhanced by
the SUMO ligase activity exerted by proteins belonging to theere transfected with an expression plasmid for EGFP fusions of either the wild-type
bination with different permutations of the plasmids pBOR, pMAL (control empty
analyzed by fluorescence microscopy or processed for DNA purification, digestion
icated DNA. (A) Cellular localization of WT and NES2M BPV E1. (B) Transient
icated. (C) In vitroDNA replication assay. Shown are the results using the amounts
indicated. The Mock samples were performed with an in vitro translation reaction
r 3 experiments. The inset shows an anti-E1 immunoblot of the in vitro translation
E1).
Fig. 9. Sumoylation enhances the interaction of BPV E1 with CRM1. (A) Cellular localization of EGFP fusions of the E1 K514R mutant (upper panel) and wild-type E1
(lower panel), as observed by confocal microscopy. (B) Pull-down assays performedwith 4μg of purifiedGSTorGST-CRM1 and2μL of in vitro translatedBPVE1 either
unmodified or modified by in vitro sumoylation. The pull-downs were performed in triplicate and all the samples are shown. The samples were analyzed by SDS-PAGE
and quantified by phosphordensitometry. Arrows 1 and 2 indicate CRM1-associated unmodified E1 from the unsumoylated and sumoylated input samples, respectively.
Arrow3 indicates CRM1-associated sumoylated E1. (C)Quantitative data indicating the percentage of input unmodified (1 and 2) or sumoylatedBPVE1 (3) that remained
bound to the beads after the pull-down procedure, as determined by phosphordensitometry of the triplicate samples presented in B. The numbers in parenthesis indicate the
location of the bands measured in each case, as shown in B.
158 G. Rosas-Acosta, V.G. Wilson / Virology 373 (2008) 149–162PIAS family (Rosas-Acosta et al., 2005). Although a previous
report indicated that a non-sumoylatable form of BPV E1
containing a Lys to Arg substitution at position 514 (referred to
as the K514R mutant) displayed a predominantly cytoplasmic
localization (Rangasamy et al., 2000), more recent extensive
experimentation using confocal microscopy has demonstrated
that the non-sumoylatable mutant is almost exclusively nuclear
and is enriched in close proximity to the nuclear envelope,
exhibiting a more dotted appearance than the wild-type form
(Fig. 9A). These findings still support a role for SUMO in the
regulation of the cellular distribution of BPV E1 albeit different
to the one previously suggested. To determine if sumoylation
affects the binding of BPV E1 to CRM1, we performed in vitro
sumoylation reactions and assessed the ability of the sumoylated
and un-sumoylated forms of BPV E1 to bind CRM1 using pull-
down assays. Interestingly, sumoylation appeared to enhance the
interaction of BPV E1 with CRM1 as the amount of un-
sumoylated BPV E1 detected in the pull-downs performed with
the sumoylated samples was larger than that detected in pull-
downs performed with un-sumoylated samples (compare the
intensity of bands 1 and 2, Fig. 9B). Furthermore, sumoylated
BPV E1 was efficiently pulled-down by CRM1 (arrow 3,
Fig. 9B), and the fraction of sumoylated BPV E1 recovered
constituted a larger fraction of the initial amount present than for
the un-sumoylated BPV E1 (Fig. 9C). Altogether, these findings
indicate that, at least under the experimental conditions employed
in our in vitro binding assays, sumoylation enhances the binding
of BPV E1 to CRM1. This finding is consistent with the
observation that wild-type BPV E1 exhibits a more abundant
cytoplasmic distribution than the K514R mutant.
Discussion
In this study we demonstrate that, similar to its human
papillomavirus counterpart HPV E1, the bovine papillomavirus
helicase protein BPV E1 shuttles between the nucleus and the
cytoplasm. Furthermore, we provide evidence for one strong
export signal, spanning residues 409–418 (NES2), whose exportactivity is mediated by the nuclear export factor CRM1.
Importantly, mutations affecting the CRM1-dependent nuclear
export signal result in a substantial increase in the nuclear
accumulation of BPV E1, but decreased replication activity as
assessed by an in vivo replication assay. Since the intrinsic
replication activity of the NES2 mutant appears normal in an in
vitro replication assay, the in vivo results suggest a requirement for
nuclear-cytoplasmic shuttling for maintenance of E1 activity.
Additionally, we identified two other nuclear export signals within
BPV E1, spanning residues 140–153 (NES3) and 262–275
(NES4). These latter two elements have only weak activity in the
context of a reporter protein, and their export activity is
independent of the nuclear export factor CRM1. We also present
data supporting an altered but still nuclear localization for the BPV
E1K514Rmutant, a previously reportedmutation known to affect
the sumoylation and replicative function of BPV E1, and demon-
strate that sumoylation enhances the interaction of BPV E1 with
CRM1 in an in vitro assay, therefore supporting a role for BPV
E1 sumoylation in regulating the cellular localization of BPV E1.
In contrast with the previous report related to the nuclear
export of HPV11 E1, which identified only one NES in HPV11
E1, in this study we identified three functional NESs in BPV E1
by using REV–GFP chimeras. Although the actual contribution
to the nuclear export of BPV E1mediated by the twoweak NESs
identified (NES3 and NES4) could not be accurately defined
based on the data presented, our results suggest that NES2 is the
main contributor to the nuclear export of BPV E1. First, NES2 is
the only NES acting via a CRM1-dependent nuclear export
pathway as the activity of NES3 and NES4 in our functional
assay was not affected by the cellular concentration of CRM1
nor by LMB treatment. Thus, NES3 and NES4's nuclear export
activity is mediated by another yet unidentified exportin. This
result was rather surprising as the sequence motif exhibited by
NES3 and NES4 correspond to that present in p27, which has
been previously reported to act on a CRM1-dependent manner
(Connor et al., 2003). Second, RNAi directed against CRM1
resulted in a significant increase in the nuclear localization of
BPV E1. Third, LMB treatment, a well established inhibitor of
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increase in BPV E1's nuclear accumulation. Finally, mutations
affecting NES2 also resulted in almost exclusive nuclear
localization of BPV E1. Thus, NES3 and NES4 appear to pro-
vide a very limited contribution to the nuclear export of BPV E1,
in agreement with their weak nuclear export activity measured in
the REV–GFP chimeras. However, it is also possible that NES3
and NES4 may be substantially more active upon BPV E1
phosphorylation, therefore providing BPV E1 with alternative
phosphorylation-dependent nuclear export pathways, as dis-
cussed below. In either case, the existence of alternative nuclear
export pathways for BPV E1 emphasizes the biological rele-
vance of this process for BPV E1 function.
The role of CRM1 in the nuclear export of BPV E1 herein
reported is consistent with previous reports by other groups.Work
by the Broker–Chow group (Deng et al., 2004) mapped a nuclear
export sequence (NES) in the HPV11 E1 protein which functions
in a CRM1-dependent way. The NES identified inHPV11 E1was
constitutively active and was inhibited by phosphorylation of a
nearby Ser residue. Importantly, the sequence motif mediating
HPV11 E1's nuclear export was mapped to a well conserved
region of the protein that is nevertheless absent in the equivalent
region of BPV E1, thus leading the authors to postulate the
absence of a CRM1-dependent nuclear export mechanism for
BPV E1. However, work by the Bonne-Andrea group demon-
strated that BPV E1 was actively exported from the nucleus, and
although an NES motif in BPV E1 was not mapped, they
presented evidence indicating that BPV E1 export occurred via a
CRM1-dependentmechanism (Hsu et al., 2007). According to the
data presented in that study, and in sharp contrast withHPV11 E1,
the nuclear export of BPV E1 did not seem constitutively active
but instead required the phosphorylation of Ser283 by an active
cyclin A–Cdk2 complex. In our present study we did not evaluate
the potential regulatory role exerted by phosphorylation on the
nuclear export of BPV E1. However, one of the functional NESs
identified, NES4 which encompasses residues 262–275, is
located just upstream of Ser283. Although NES4 is one of the
two weakest NES elements identified in BPV E1, it is possible
that phosphorylation of Ser283 may increase its activity
substantially. Likewise, though NES2, which spans residues
409–418, is more active than NES4when expressed in the REV–
GFP chimeric constructs, it is possible the phosphorylation could
enhance its activity even further. Direct testing of the effect of
phosphorylation on the strength of NES2 and the other two
functional NESs identified will be required to determine if these
NESs are affected by phosphorylation as suggested by previous
publications (Hsu et al., 2007) (Deng et al., 2004).
Mechanisms dictating the cellular localization of BPVE1 have
been postulated to be the main contributors to the regulation of
BPV E1 function (Bian et al., 2007; Hsu et al., 2007; Yu et al.,
2007). Previous studies focused on the regulation of the nuclear
localization of BPV E1 and HPV E1 have shown a tight
correlation between the abundance of the E1 helicase in the
nucleus and the replication of plasmids containing a papilloma-
virus origin of replication (Deng et al., 2004; Yu et al., 2007).
Importantly, this was not the case for the NES2 mutant developed
in this study. The BPV E1NES2Mmutant protein, containing theI413A/L416A substitutions, which inactivate NES2 as deter-
mined with the REV–GFP chimera, appeared to accumulate in
the nucleus up to a higher concentration than the wild-type
protein. However, the NES2M mutant exhibited a significantly
reduced replication activity compared to that of the wild-type
protein in a transient in vivo BPV DNA replication assay, even
though this mutant E1 protein appeared functionally normal for
replication activity in vitro. Consistent with the in vitro results,
the NES2M mutations introduced on BPV E1 are located on an
externally exposed alpha helical structure in BPV E1, and do not
appear to be located near regions required for single or double-
strand DNA binding or protein oligomerization, based on the
crystallographic data reported by Enemark and Joshua-Tor (Ene-
mark and Joshua-Tor, 2006). In addition, a previously constructed
deletion mutant missing 4 amino acids within the NES2 motif
(residues 412–415) hadwild-typeDNAbinding andATP binding
activity, though was also severely impaired for transient repli-
cation similar to NES2M (Ludes-Meyers, 1995). Thus, the region
mutated in NES2M appears to have little or no direct contribution
to E1 enzymatic function, which suggests that continuous nuclear
import and export of BPV E1may be an important requirement to
maintain its activity. One hypothetical scenario that could explain
this requirement is that the continuous shuttling of BPV E1 may
prevent its sequestration in replication-inactive nuclear subdo-
mains. The existence of such subdomains is suggested by the
dotted nuclear structures containing BPV E1 observed in the
NES2M mutant.
Previous studies by our group had indicated that the nuclear
localization of BPV E1 was dependent upon sumoylation. Now
we have re-evaluated those findings and have concluded that
sumoylation affects the sub-nuclear localization and cellular
distribution of BPV E1 but is not required for its nuclear loca-
lization, as the K514R mutant (previously shown to be non-
sumoylatable in vivo) is localized in the nucleus. Importantly, we
have observed that BPV E1 sumoylation enhances BPV E1's
interaction with CRM1 in in vitro pull-down assays. The increase
in the amount of unmodified BPV E1 retained by CRM1 in the
presence of sumoylatedBPVE1may be due to oligomerization of
the SUMO-modified form of BPV E1 with unsumoylated forms
of BPV E1. Thus, sumoylation may enhance the nuclear export of
BPV E1, as suggested by the observed cellular distribution of the
WT and the K514R mutant proteins. Sumoylation is already
known to play a role in the nuclear export of other proteins: the
nuclear export of the Dictyostelium discoideumMEK1 protein is
dependent upon sumoylation (Sobko et al., 2002), the intranuclear
targeting and nuclear export of the adenovirus E1B-55K protein
are regulated by sumoylation (Kindsmuller et al., 2007), SUMO
conjugation regulates the nuclear export of the putative tumor
suppressor protein TEL (Wood et al., 2003), and cycles of SUMO
conjugation and de-conjugation appear to regulate the nuclear
shuttling of hnRNPs (Vassileva and Matunis, 2004). Most
proteins exported from the nucleus using a CRM1-dependent
pathway establish weak unstable interactions with CRM1 (Kutay
and Guttinger, 2005), and NESs able to establish stable
complexes with CRM1 appear trapped in a complex with
CRM1 at the nuclear pore complex (Engelsma et al., 2004).
This is to our knowledge the first direct demonstration that
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shuttling protein. This finding supports the possibility that cycles
of sumoylation and de-sumoylation may play a role in nuclear
shuttling as previously postulated by Vassileva and Matunis
(Vassileva and Matunis, 2004), as a sumoylated protein would
likely remain bound to CRM1 until de-sumoylated by a SUMO-
protease. This is further supported by previous reports indicating
the localization of different components of the sumoylation
system, including SUMO conjugating and SUMOde-conjugating
enzymes, and ligases, to the nuclear pore complex (Hang and
Dasso, 2002; Panse et al., 2003; Pichler et al., 2002; Takahashi
et al., 2000; Zhang et al., 2002). Further studies aimed at clarifying
the role played by sumoylation in the regulation of traffic across
the nuclear pore complex are likely to reveal intriguing aspects of
the biological events dictating this process and have the potential
to reveal novel targets for therapeutic approaches to infectious
diseases and cancer.
Materials and methods
Cell lines, transfections, fluorescence microscopy, and confocal
fluorescence microscopy
HeLa and Cos1 cells were maintained in 1× DMEM
supplemented with 10% FetalPlex™ (Gemini BioProducts,
West Sacramento, CA). CHO-K1 cells were maintained in 1×
Ham's F12K supplemented with 10% FetalPlex™. All transfec-
tions were performed using Lipofectamine™ 2000 (Invitrogen
Corp., Carlsbad, CA), according to the manufacturer's protocol.
Fluorescence microscopy was performed with a Nikon Eclipse
TS 100 microscope (Nikon Inc., Melville, NY) using an X-
Cite™ 120 Fluorescence Illumination System (EXFP America
Inc., Plano, TX) and a Nikon Digital Sight DS 2 Mv camera
(Nikon Inc.). Confocal fluorescence microscopy was performed
on a Zeiss Axiovert 135 microscope (Carl Zeiss MicroImaging,
Inc., Thornwood, NY) with a CARV confocal module (Zeiss
MicroImaging and Atto Bioscience) and images were collected
at 0.75-μm intervals using Zeiss AXIOVISION 3.1.
RNAi and reporter constructs
Candidate sequences to develop effective RNAi constructs to
human CRM1 (NM_003400) were obtained from Ambion
(Ambion, Austin, TX). The sequences obtained contained addi-
tional sequence elements, including inverted repeats designed to
generate hairpins with a 19-nucleotide stem and a 9-nucleotide
loop, and sequences for cloning into the pSilencer™ 4.1-CMV
puro vector (Ambion). The sequences of the oligonucleotides
used to develop the two different RNAi constructs are indicated
below. pSIL-CRM1A construct: Forward primer, 5′ GATCCG-
GAGC CCAGCAAAGA ATGGTTCAAG AGACCATTCT
TTGCTGGGCT CCTTA 3′; Reverse primer, 5′ AGCTTA-
AGGA GCCCAGCAAA GAATGGTCTC TTGAACCATT
CTTTGCTGGG CTCCG 3′. pSIL-CRM1B construct: Forward
primer, 5′ GATCCGGAGC ATCCTGATGC TTGGTTCAAG
AGACCAAGCATCAGGATGCT CCTTA 3′; Reverse primer,
5′ AGCTTAAGGA GCATCCTGAT GCTTGGTCTCTTGAACCAAG CATCAGGATG CTCCG 3′. To map the nu-
clear export sequences (NESs) contained within BPV E1, we
introduced an adaptor sequence between the BamHI and AgeI
sites on the plasmid pREV1.4(NES3)GFP developed by Hen-
derson and Eleftheriou (Henderson and Eleftheriou, 2000). The
adaptor sequence was produced by annealing the complemen-
tary primers Adpt.FW (5′ GATCGACCAC CTGTACCACT
GGATCCGCGG GGACCGGTAG ATTGCAAC 3′) and Adpt.
RV (5′ CCGGGTTGCA ATCTACCGGT CCCCGCGGAT
CCAGTGGTAC AGGTGGTC 3′). The adaptor sequence intro-
duced mutations in the original BamHI and AgeI sites, contained
a sequence coding for the sequence surrounding the NES con-
tained in the REV-HIV protein, and provided a new set of
BamHI and AgeI sites. The resulting plasmid produced was
denominated pREV/GFP/Adpt and was used for the subsequent
expression of all the putative NESs identified within BPV E1. To
this end, sequences coding for the putative NESs were intro-
duced into BamHI/AgeI digested pREV/GFP/Adpt as comple-
mentary oligonucleotides recreating sticky BamHI and AgeI
ends upon annealing (precise sequences available on request).
Constructs containing substitutions of specific bulky hydro-
phobic in the putative NESs were developed in a similar manner.
Nuclear export assay
Nuclear export assays were performed following a combina-
tion of the procedures described by Connor et al. (Connor et al.,
2003) and Love et al. (Love et al., 1998). Briefly, HeLa cells were
plated on 6 cmPetri dishes at a density of 1×106 cells per dish and
transfected 24 h later with the plasmid pEGFP–E1 (coding for a
fusion of EGFP and the BPV E1 protein) using Lipofectamine™
2000. Twenty four hours post-transfection the cells were washed
twice with 1× Transport Buffer (1× TB; 20 mM Hepes pH 7.8,
2 mM EGTA, 110 mM Potassium Acetate, 2 mM Magnesium
Acetate), and permeabilized by incubation for 5 min at room
temperature in 1 mL of 1× TB supplemented with Digitonin at
50 μg/mL, a 1:200 dilution of Protease Inhibitor Cocktail P8340
(Sigma-Aldrich Co., Saint Louis, MO), and 10 μMMG-132. The
cells were washed twice (1 min per wash at room temperature)
with 5 mL of 1× TB, and incubated in 1 mL of 1× TB
supplemented with a 1:500 dilution of Protease Inhibitor Cocktail
P8340, 5 mMATP, 2 mMGTP, 5 mMCreatine Phosphate, 20 U/
mL Creatine Phosphokinase, and 2 mM DTT, with or without
20% Reticulocyte Extract (from the TnT® T7 in vitro translation
system, Promega Corp., Madison, WI). One hour later, the resul-
ting supernatant (exported fraction) was collected and immuno-
precipitated using 5 μL of anti-GFP rabbit polyclonal antibody
and 40 μL of Protein G-Plus bead slurry (both from Santa Cruz
Biotechnology Inc., Santa Cruz, CA). The permeabilized cells
were washed once more with 1× TB, and collected in 500 μL of
2× Sample Buffer (100 mM Tris pH 6.8, 20% glycerol, 8% SDS,
0.02% bromophenol blue, 4% β-mercaptoethanol). The resulting
cell lysate and the immunoprecipitated samples were resolved
on a 10% SDS-PAGE gel, transferred to an Immobilon™
PVDF membrane (Millipore Corp., Billerica, MA), and
probed with an anti-GFP monoclonal antibody (Santa Cruz
Biotechnology Inc.).
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Pull down assays and in vitro sumoylation assays were
performed as previously reported (Rosas-Acosta et al., 2005).
For pull down analysis of in vitro sumoylated samples, upon in
vitro sumoylation the full in vitro sumoylation reaction volume
was diluted in 1× TBS supplemented with 5 mMMgCl2, 0.05%
Tween 20, and 5 mg/mL BSA, and incubated for 3 h at 4 °C
with 20 μL of packed Glutathione–Sepharose beads and 4 μg of
the indicated purified protein (either GST or GST-CRM1) in a
final volume of 500 μL. The beads were washed four times with
1× TBS supplemented with 0.05% Tween 20 and 5 mMMgCl2,
the remaining supernatant was discarded, and the beads were
resuspended in 25 μL of 4× Sample Buffer, resolved by SDS-
PAGE on a 10% gel, blotted into an Immobilon™ PVDF
membrane, and analyzed by phosphordensitometry as pre-
viously described (Rosas-Acosta et al., 2005).
Biochemical fractionation
CHO-K1 cells were transfected with pEGFP–E1 as for the
nuclear export assay and harvested 24 h post-transfection. Four
hours prior to harvest, leptomycin B (LMB) and cycloheximide
were added to the medium at a final concentrations of 20 ng/ml
and 10 ng/ml, respectively. Cells were harvested by scraping into
ice-cold PBS, pelleted, and washed 1 time with 1 ml of ice-cold
PBS. The washed pellet was resuspended in 200 μL of hypotonic
buffer (10 mM Tris–HCl, pH 7.5, 10 mM KCl, 1.5 mM MgCl2,
0.25% Triton X100), incubated 10 min on ice, and then lysed by
25 strokes with a Dounce homogenizer. The lysed cells were
centrifuged for 4min at 2000 ×g and the supernatant was removed
as the cytosolic fraction. The nuclear pellet was washed 1 time
with 500 μL of hypotonic buffer, resuspended in 150 μL of
hypotonic buffer, and lysed by addition of 50 μL of 4× SDS
sample buffer to yield the nuclear fraction. The fractionation
efficiencywas evaluated by examination of endogenous RanGAP
and was greater than 90% (not shown).
Transient replication assays
The transient HPV DNA replication assays were performed
following a modification of the procedures previously described
by Titolo et al. (Titolo et al., 2003, 2000). Briefly, approximately
1×106 CHO-K1 cells were plated on 6 well plates. Twenty four
hours later, the cells were transfected with 4 μL of Lipofecta-
mine™ 2000 and 2 μg of different combinations of plasmids
encoding, respectively, E1 (pEGFP–E1WT), a previously
reported mutant form of E1 containing a Lys to Arg substitution
at residue 514 (pEGFP–E1 K514R), a mutant form of E1
containing Ala substitutions affecting NES2 (pEGFP–NES2M),
E2 (pCGE2), a plasmid containing the HPVori region (pBOR),
and an empty plasmid lacking mammalian promoters (pMAL-
c2E). The pCGE2, pBOR, and the various E1 plasmids were
transfected at a ratio of 0.2:1:1, respectively. Seven hours post-
transfection, the cells were treated with 500 μL of tissue-culture
trypsin, washed with complete Ham's F12K, and plated in 10 cm
Petri dishes. The cells were subsequently incubated at 37 °C and5% CO2 for another 65 h. At 72 h post-transfection the cells were
collected by trypsinization and washed in ice cold 1× PBS. The
wet cell pellets obtainedwere stored at−20 °C until used for DNA
purification. DNA was purified using the QIAamp DNA Blood
Midi purification kit (QIAGEN Inc, Valencia, CA), as indicated
by themanufacturer. PurifiedDNAwas eluted off the spin column
by two rounds of elution using 300 μL of elution buffer each.
Approximately equal DNA concentrations of total genomic DNA
(∼250 ng/μL) were obtained for all samples as determined by
spectrophotometry. Replicated pBOR plasmid was detected by
PCR amplification of a region containing 5 DpnI restriction sites.
To this end, 21 μL of the purified genomic DNA were digested
with 10 U of DpnI for 16 h at 37 °C in a final volume of 25 μL.
Then, 10 μL of the digestion mix (∼25 ng gDNA) were used as
template for the PCR reaction. Four primers were used in each
PCR reaction, two amplifying a ∼507 bp region void of DpnI
sites in the E1 gene contained in the pEGFP–E1 plasmids, and
two amplifying a∼952 bp region containing the indicated 5 DpnI
restriction sites in the pBOR plasmid. The sequences of the E1
primers were 5′ TCGGTATGATAGCCAGGATGAGG 3′ and 5′
CTTCTTTAGGAGTTCGAAACTCGCC 3′, and the sequences
of the pBOR plasmid primers were 5′ TTCTTCGGGGCGAA-
AACTCTCAAGG 3′ and 5′ GATTACGAATTCGAGCTCGG-
TACCC 3′. Each primer was added at a final concentration of
0.5 μM, and each PCR reaction had a final volume of 50 μL. To
allow the detection and precise quantification of the amplified
products, 5 μCi of [α-32P] dCTP was added to each reaction. The
PCR conditions used consisted of an initial denaturation at 95 °C
for 3 min, followed by 23 cycles of denaturation at 95 °C for
15 sec, annealing at 55 °C for 30 sec, and extension at 72 °C for
1 min. The use of 23 cycles of PCR amplification was deemed
optimal during initial standardizations. After the final cycle, the
samples were incubated at 72 °C for 10min, and kept at 4 °C. The
PCR products were analyzed on a 1 mm thick 3.5% acrylamide
gel containing 1× TBE buffer, by loading 3 μl of the PCR
products per lane. The gel was fixed in a 10% acetic acid solution
for 10 min, dried, and analyzed by phosphordensitometry as
previously described (Rosas-Acosta et al., 2005).
In vitro replication assay
Assays were performed using in vitro translation reactions as
the source of E1 proteins as previously described (Amin et al.,
2000). In vitro translation was performed using the TnT T7Quick
Coupled Transcription/Translation kit (Promega Corp.). The cell
extracts for the replication assay were prepared by the procedure
of Wang and Wang (Wang and Wang, 1999). Replication assays
were performed for 90 min at 37°C, and the extent of DNA
synthesis was monitored by scintillation counting of 32P-dCMP
incorporated into TCA precipitated nucleic acid. Results shown
are the average of 2–3 experiments for each sample.
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